Literature DB >> 8417826

Interstitial chemotherapy of the 9L gliosarcoma: controlled release polymers for drug delivery in the brain.

R J Tamargo1, J S Myseros, J I Epstein, M B Yang, M Chasin, H Brem.   

Abstract

The administration of drugs directly into the central nervous system using polymers as drug carriers may improve the treatment of malignant brain tumors. In this study, the effect of the interstitial, localized delivery of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) incorporated into controlled release polymers implanted adjacent to the 9L gliosarcoma was assessed in s.c. and intracranial (i.c.) models. In the s.c. experiment, the 9L gliosarcoma was implanted in the flank of rats and subsequently treated with BCNU either (a) delivered in controlled release polymers inserted adjacent to the tumor or (b) administered systemically by i.p. injections or by controlled release polymers inserted at a site distant from the tumor. The interstitial release of BCNU adjacent to the tumor in the flank resulted in a significant tumor growth delay of 16.3 days, as compared to a growth delay of 9.3 and 11.2 days obtained with the systemic administration of BCNU. In the i.c. experiment, the 9L gliosarcoma was implanted in the brain of Fischer 344 rats and treated either (a) with controlled release polymers containing BCNU inserted into the brain or (b) with the systemic i.p. administration of BCNU. The interstitial release of BCNU in the brain resulted in a significant 5.4- to 7.3-fold increased survival, compared with a 2.4-fold increased survival after the systemic administration of the same dose of BCNU. The two groups with i.c. tumors treated interstitially had 17 and 42% cures, but no long-term cures were obtained in the group treated with systemic therapy. The localized, controlled delivery of chemotherapeutic agents in the s.c. tissues and in the brain via polymeric carriers may be more effective than standard systemic chemotherapy. This approach could be used to deliver a wide variety of agents into the central nervous system to treat diverse neuropathological conditions which remain refractory to systemic therapy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8417826

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  50 in total

1.  Preparation and characterization of carmustine loaded polyanhydride wafers for treating brain tumors.

Authors:  A J Domb; Z H Israel; O Elmalak; D Teomim; A Bentolila
Journal:  Pharm Res       Date:  1999-05       Impact factor: 4.200

2.  Liposome-mediated therapy of intracranial brain tumors in a rat model.

Authors:  U S Sharma; A Sharma; R I Chau; R M Straubinger
Journal:  Pharm Res       Date:  1997-08       Impact factor: 4.200

Review 3.  Novel delivery strategies for glioblastoma.

Authors:  Jiangbing Zhou; Kofi-Buaku Atsina; Benjamin T Himes; Garth W Strohbehn; W Mark Saltzman
Journal:  Cancer J       Date:  2012 Jan-Feb       Impact factor: 3.360

4.  Fenofibrate subcellular distribution as a rationale for the intracranial delivery through biodegradable carrier.

Authors:  M Grabacka; P Waligorski; A Zapata; D A Blake; D Wyczechowska; A Wilk; M Rutkowska; H Vashistha; R Ayyala; T Ponnusamy; V T John; F Culicchia; A Wisniewska-Becker; K Reiss
Journal:  J Physiol Pharmacol       Date:  2015-04       Impact factor: 3.011

Review 5.  Interstitial chemotherapy for malignant gliomas: the Johns Hopkins experience.

Authors:  H Christopher Lawson; Prakash Sampath; Eileen Bohan; Michael C Park; Namath Hussain; Alessandro Olivi; Jon Weingart; Lawrence Kleinberg; Henry Brem
Journal:  J Neurooncol       Date:  2006-12-14       Impact factor: 4.130

6.  Injectable chemotherapeutic microspheres and glioma II: enhanced survival following implantation into deep inoperable tumors.

Authors:  D F Emerich; S R Winn; P Snodgrass; D LaFreniere; M Agostino; T Wiens; H Xiong; R T Bartus
Journal:  Pharm Res       Date:  2000-07       Impact factor: 4.200

7.  Extreme drug resistance in primary brain tumors: in vitro analysis of 64 resection specimens.

Authors:  Raymond I Haroun; Richard E Clatterbuck; M Christopher Gibbons; Peter C Burger; Ricardo Parker; John P Fruehauf; Henry Brem
Journal:  J Neurooncol       Date:  2002-06       Impact factor: 4.130

8.  Combination of paclitaxel thermal gel depot with temozolomide and radiotherapy significantly prolongs survival in an experimental rodent glioma model.

Authors:  Ananth K Vellimana; Violette Renard Recinos; Lee Hwang; Kirk D Fowers; Khan W Li; Yonggang Zhang; Saint Okonma; Charles G Eberhart; Henry Brem; Betty M Tyler
Journal:  J Neurooncol       Date:  2012-12-07       Impact factor: 4.130

9.  Intralesional mitoxantrone biopolymer-mediated chemotherapy prolongs survival in rats with experimental brain tumors.

Authors:  Marco Saini; Florian Roser; Samii Hussein; Madjid Samii; Mattia Bellinzona
Journal:  J Neurooncol       Date:  2004-07       Impact factor: 4.130

10.  Local delivery of minocycline and systemic BCNU have synergistic activity in the treatment of intracranial glioma.

Authors:  James L Frazier; Paul P Wang; Daniel Case; Betty M Tyler; Gustavo Pradilla; Jon D Weingart; Henry Brem
Journal:  J Neurooncol       Date:  2003-09       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.